All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

GLP-1 adoption in Colorado

Colorado has an estimated 205,374 GLP-1 users across 64 counties. Average estimated adoption is 2.1 percentage points below the national rate of 5.7%.

Last reviewed |Reviewed by the FormBlends Editorial Standards Team

3.6%

Est. adoption rate

205,374

Est. users

26.1%

Avg adult obesity

5,770,790

Adult population

State facts for search and AI answers

What makes the Colorado GLP-1 page useful

This page ties the statewide answer to county-level demand, coverage context, and practical access checks. The goal is to help readers move from a broad state estimate to the local county or provider question that actually matters.

State signal

Colorado: 64 counties, 205,374 estimated GLP-1 users

State pages summarize the county-level demand model before readers drill into local pages.

Model inputs

Average adoption 3.6%; average adult obesity 26.1%

The model uses CDC PLACES obesity prevalence, Census population, and KFF national GLP-1 utilization.

Coverage context

Colorado Medicaid does not cover GLP-1s for obesity. Coverage for T2D, cardiovascular disease, and sleep apnea indications is still available. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.

Coverage policy can make real access higher or lower than projected local demand.

How to use this page

Find counties with the strongest demand signal, then verify coverage, provider access, and pharmacy source before starting care.

This is a local planning page, not a prescription recommendation.

Counties ranked by estimated adoption

Adoption strip: each bar is one county, tallest = highest estimated rate
County adoption strip. Tallest bar = highest projected adoption in Colorado.
Ranked counties in Colorado by estimated GLP-1 adoption.
RankCountyPopulationObesity %Est. adoptionEst. users
1Otero18,58035.1%4.8%888
2Bent5,56134.0%4.6%257
3Weld331,46633.6%4.6%15,148
4Adams520,14933.0%4.5%23,355
5Las Animas14,42232.9%4.5%646
6Morgan29,04532.3%4.4%1,278
7Pueblo168,13532.3%4.4%7,398
8Alamosa16,46032.1%4.4%719
9Costilla3,53431.7%4.3%152
10Crowley5,78231.5%4.3%248
11Conejos7,55330.5%4.2%313
12Fremont49,10730.4%4.1%2,033
13Baca3,49630.3%4.1%144
14Logan21,30230.3%4.1%878
15Mesa156,13130.1%4.1%6,401
16Lincoln5,58329.9%4.1%227
17Prowers11,96829.8%4.1%486
18Kit Carson7,03929.7%4.0%284
19Jackson1,44029.5%4.0%58
20Phillips4,49329.4%4.0%180
21Saguache6,45428.8%3.9%253
22Cheyenne1,72628.7%3.9%67
23Yuma9,93828.7%3.9%389
24El Paso730,32328.5%3.9%28,337
25Montezuma26,07028.5%3.9%1,012
26Sedgwick2,39128.5%3.9%93
27Moffat13,23228.3%3.9%509
28Huerfano6,89627.9%3.8%262
29Rio Grande11,44227.9%3.8%435
30Montrose42,82327.7%3.8%1,614
31Kiowa1,34727.6%3.8%51
32Archuleta13,50927.2%3.7%500
33Dolores2,32927.1%3.7%86
34Delta31,17326.9%3.7%1,141
35Rio Blanco6,51126.7%3.6%236
36Washington4,81726.6%3.6%174
37Custer4,88526.3%3.6%175
38Arapahoe654,45325.9%3.5%23,102
39San Juan69025.8%3.5%24
40Chaffee19,56425.4%3.5%677
41San Miguel8,08225.3%3.4%278
42Mineral79425.1%3.4%27
43Gunnison17,01824.7%3.4%572
44Douglas360,20624.6%3.4%12,067
45Larimer359,36324.4%3.3%11,931
46Elbert26,45724.1%3.3%868
47Gilpin5,85624.1%3.3%192
48Hinsdale91123.9%3.3%30
49Garfield61,68323.8%3.2%1,999
50Grand15,72423.8%3.2%509
51Lake7,40323.7%3.2%239
52Summit30,95523.7%3.2%1,000
53Eagle55,65023.6%3.2%1,786
54Teller24,75823.4%3.2%790
55Clear Creek9,40323.2%3.2%297
56Routt24,94423.0%3.1%781
57Jefferson580,51922.9%3.1%18,112
58Ouray4,93622.8%3.1%153
59Park17,59722.5%3.1%538
60Broomfield73,94622.1%3.0%2,226
61Denver710,80021.6%2.9%20,898
62La Plata55,98320.8%2.8%1,584
63Pitkin17,32520.3%2.8%478
64Boulder328,65817.4%2.4%7,789

How Colorado fits the national picture

The KFF 2024 poll pegged national adult GLP-1 use at 5.7%. Applied to Colorado's obesity profile, the model projects 3.6% of adults are on a GLP-1 medication. That matches the county-level obesity data from CDC PLACES (2023) more than any measured prescription count; the state's real share could be higher in urban areas with broad commercial coverage, or lower in rural regions where prescriber access is limited.

Compounded semaglutide and tirzepatide complicate the picture. After the FDA shortage resolution in late 2024 and early 2025, compounded supply dropped sharply. Brand-name utilization rose. The county numbers here don't separate brand vs. compounded, because no public dataset does yet.

Decision path

How should I use the Colorado GLP-1 map?

This state view is a demand and access signal, not a prescription recommendation. Use it to understand where GLP-1 need may be concentrated, then pressure-test provider availability, insurance rules, and pharmacy quality before starting care.

State
Colorado
Counties
64
Est. users
205,374
Avg adoption
3.6%

Step 1

Find county context

County estimates help separate broad statewide demand from the local access picture a patient actually experiences.

Review counties

Step 2

Check coverage and price

Colorado access depends on payer policy, prior authorization, cash-pay pricing, and whether local clinicians can support follow-up.

Check coverage path

Step 3

Decide on care route

If local access is thin or pricing is unclear, a supervised telehealth assessment can clarify eligibility and next steps.

Compare provider options
Start provider review in ColoradoReview pharmacy oversight

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

CDC PLACES

Dataset

Used for county-level obesity inputs in local GLP-1 adoption estimates.

KFF GLP-1 utilization polling

Dataset

Used as the national anchor for estimated GLP-1 adoption.

STEP 1 semaglutide obesity trial

Trial

Primary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.

Frequently asked questions

How is GLP-1 adoption calculated for Colorado counties?
We multiply each county's CDC PLACES 2023 adult obesity prevalence by a scaling factor k = 0.1361, which comes from the KFF 2024 figure of 5.7% national GLP-1 adoption divided by the 41.9% national adult obesity rate. That gives an estimated per-county adoption %. Multiply by Census ACS 5-year 2022 county population to get projected users. Colorado shows 3.6% state-average adoption under this model.
Why is Colorado's number 2.1 percentage points below the national average?
Adult obesity prevalence in Colorado averages 26.1% (CDC BRFSS 2024, state-level). The national average is 41.9%. The model links adoption linearly to obesity, so states above the national obesity rate come out above the national adoption estimate, and vice versa. Real variation also depends on commercial insurance coverage and Medicaid GLP-1 policy, both of which differ significantly by state.
Do Medicaid enrollees in Colorado get GLP-1 coverage?
Colorado Medicaid does not cover GLP-1s for obesity. Coverage for T2D, cardiovascular disease, and sleep apnea indications is still available. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.
What studies back up GLP-1 weight loss expectations?
The STEP 1 trial (Wilding et al., NEJM, 2021) enrolled 1,961 adults on 2.4mg weekly semaglutide over 68 weeks and saw mean body weight change of negative 14.9% vs negative 2.4% on placebo. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) tested tirzepatide in 2,539 adults over 72 weeks and saw negative 20.9% at 15mg weekly. Both were randomized, double-blind, and placebo-controlled.
How often does the Colorado county data refresh?
CDC PLACES releases annually in late summer. Census ACS 5-year estimates release every December. KFF reruns its GLP-1 utilization poll roughly twice a year. We re-run the full county model whenever any of those update, and the last-reviewed date at the top of every page reflects the most recent refresh.

Sources

Related reading

glp1

Compounded Semaglutide Guide

How compounded semaglutide access works, what to ask a pharmacy, and how to compare safety and pricing.

glp1

Semaglutide Cost Comparison

Compare semaglutide pricing across brand, insurance, cash-pay, and compounded access paths.

experience

Tirzepatide Side Effects Complete Guide

Common tirzepatide side effects, warning signs, and practical management steps to discuss with a clinician.

glp1

Semaglutide Injection Sites

How to rotate semaglutide injection sites and reduce irritation, bruising, and technique problems.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

2026 GLP-1 Telehealth Report

105 providers scored on price, safety, compliance, and patient experience.

Compounded GLP-1 ZIP Lookup

State pharmacy-board posture and telehealth access for US ZIP codes.

America on GLP-1 Map

County-level adoption estimates using CDC, Census, and KFF inputs.

Looking for GLP-1 care in Colorado?

FormBlends ships compounded semaglutide and tirzepatide to Colorado with licensed telehealth consultations.

Start your assessment

Estimated adoption figures are modeled projections from public data, not measured prescription counts. This page is general information, not medical advice. Individual results vary. Talk to a licensed healthcare provider before starting any medication.